Oxford

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241

This Phase 1 clinical trial is investigating a new type of immunotherapy called RP2 for people with advanced solid tumours, including metastatic uveal melanoma. RP2 is an engineered herpes simplex virus (HSV-1) designed to infect and destroy cancer cells while also stimulating the body’s immune system to recognise and attack the tumour. The treatment has […]

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241 Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886

DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886 Read More »

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) – NCT05315258

Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) – NCT05315258 Read More »